

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease ID3821

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Akebia Therapeutics (vadadustat) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Kidney Care UK • Kidney Research UK • National Kidney Federation • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Anaemia Nurse Specialist Association • Association of Renal Technologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Committee for Standards in Haematology • British Society for Genetic Medicine • British Geriatrics Society • British Society for Haematology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders • UK Kidney Association • UK National Screening Committee • UK Renal Pharmacy Group 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Amgen UK (darbepoetin alfa) • Janssen-Cilag (epoetin alfa) • Pfizer (epoetin zeta) • Roche Products UK (epoetin beta, methoxy polyethylene glycol-epoetin beta) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney and Transplant Group • Cochrane UK

Provisional stakeholder list for the evaluation of vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease ID3821

Issue date: December 2023

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • United Kingdom Primary Immunodeficiency Network • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG)..

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.